Laura Vergani joins the international biopharmaceuticals group after working with big names including Walgreens Boots Alliance, Barclays, and Standard & Poor’s.
MSD and Curon have announced that they have entered into a definitive agreement under which MSD has agreed to acquire CN201, a novel investigational clinical-stage bispecific antibody for the treatment of B-cell associated diseases.
Alcura, a provider of specialised clinical trial services and a part of Cencora, has been granted a Manufacturing and Importation Authorization (MIA) license for cell and gene therapies (CGT) by the Spanish Agency of Medicines and Medical Devices.
Otsuka Pharmaceuticals is collaborating with Health Innovation Oxford HIN to evaluate the implementation and integration of a new digital therapeutic (DTx), CARE for MDD, intended to support the treatment of major depressive disorder (MDD).
Cresset, a provider of integrated in silico solutions for drug discovery announces the release of V9 - the latest version of its Flare platform for ligand-based and structure-based design, which includes a full integration of Spark.
